Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
The oral presentation given by Dr. Brian Van Tine of the Washington University School of Medicine is available on-demand for congress attendees.
- The oral presentation given by Dr. Brian Van Tine of the Washington University School of Medicine is available on-demand for congress attendees.
- Dr. Van Tine will also participate in a live stream session entitled - Immunotherapy in Sarcoma: Alveolar Soft Part Sarcoma, Clear Cell Sarcoma, Synovial Sarcoma (Proffered Papers Panel Discussion) scheduled for 9 AM EST today (November 19).
- The impact on patients treated with ADP-A2M4 is transformative, as they benefit from a durable response from a single treatment.
- Data presented at CTOS were updated durability of response and safety data from the 16patients with synovial sarcoma who were treated in the Phase 1 ADP-A2M4 trial, presented earlier this year at ASCO.